A Phase I/IIa Study of C5252 in Patients With Intracranial Tumor

NCT ID: NCT07243340

Last Updated: 2025-11-21

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 36 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-12-15
• Study Completion Date: 2028-12-15

Brief Summary

This study includes phase I dose escalation part and phase IIa dose expansion part. The goal of this clinical trial is to learn if C5252 treatment is safe and well tolerated in patients with intracranial tumor and to learn preliminary efficacy of C5252. In this study, participants will be given single or multiple doses of C5252 according to protocol followed by toxicity observation, safety follow-up and long-term follow-up.

Conditions

Glioma, Malignant

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Herpes Virus C5252 Injection

Group Type: EXPERIMENTAL

Herpes Virus C5252 Injection

Intervention Type: BIOLOGICAL

C5252 will be administered at designed dose level.

Interventions

Herpes Virus C5252 Injection

C5252 will be administered at designed dose level.

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Age ≥ 18 years.
• Confirmed recurrent malignant high-grade (WHO grade 3-4) glioma who have received standard therapy and no available treatment.
• Measurable lesions exist in accordance with RANO criteria.
• Sufficient space for ≥1 mL drug infused into tumor cavity post resection.
• Ommaya reservoir has been placed in the operation area, and drug administration conditions are available.
• Karnofsky Performance Status (KPS) ≥ 60%
• Life expectancy > 12 weeks.
• No severe hematological, cardiovascular, liver or kidney diseases.
• If the patient is a sexually active female of childbearing potential or if the patient is a sexually active male whose partner is a female of childbearing potential, the patient must use appropriate contraceptive measures for the duration of the treatment and for 6 months afterwards. Female patients of childbearing potential must have a negative serum pregnancy test within 7 days of before the C5252 infusion.
• Capable of understanding and complying with protocol requirements.

Exclusion Criteria

• Inability to undergo MRI examination for any reason.
• Active hemorrhage observed before enrollment.
• Imaging test: a. lesion located in non-cerebral regions; b. there are other lesions outside target tumor cavity; c. extra-cranial metastasis.
• Tumor lesion locates in ventricular system or there is a clear perforation between the tumor cavity and the ventricle after tumor resection.
• History of encephalitis, multiple sclerosis or other central nervous system infections
• Treated with steroid hormones and/or more than 5 mg dexamethasone per day or other immunosuppressive drugs for systemic treatment within 4 weeks.
• Persistent or active infection, and cannot be controlled by treatment.
• Subjects with bleeding tendency or need to take anticoagulant drugs, antiplatelet drugs or non-steroidal anti-inflammatory drugs (NSAIDs) and are unable to discontinue.
• Uncontrolled disease, including but not limited to symptomatic congestive heart failure, unstable angina pectoris.
• Other malignant tumor within 5 years.
• Patients who require an attenuated or live vaccine within 28 days prior to the first trial drug administration and during the study treatment period.
• In the period of recurrent herpes simplex virus infection, with corresponding clinical manifestations.
• Systemic use (other than topical) of anti-HSV drugs
• Prior treatment with any oncolytic virus, cell therapy or gene therapy.
• Participants have a history of splenectomy, organ transplantation, bone marrow transplantation or stem cell transplantation
• Prior antitumor treatment with intracranial implants, such as Carmustine.
• Previous history of allergic reactions to similar biological components such as HSV-1, IL-12 or anti-PD-1 antibodies, or with known allergic reactions to any component of the C5252 prescription, including glycerol.
• Developed ≥Grade 3 irAE during previous immunotherapy
• History of frequent drug use (including "recreational use") or drug abuse (including alcohol abuse) within one year prior to signing the informed consent form.
• Other situation that PI consider subjects not appropriate to participate in the study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

ImmVira Pharma Co. Ltd

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Tianjin Medical University Cancer Institute & Hospital

Tianjin, Tianjin Municipality, China

Countries

China

Central Contacts

Xinyi Liu

Role: CONTACT

xinyi.liu@immviragroup.com

86+512+66202028

Facility Contacts

Wenliang Li

Role: primary

xinyi.liu@immviragroup.com

86+512+66202028

Role: backup

xinyi.liu@immviragroup.com

Other Identifiers

MVR-C5252-003

Identifier Type: -

Identifier Source: org_study_id